We are an international biotechnology company that is focused in the field of regenerative medicine. We are committed to developing therapeutic products that we believe have best-in-class potential, meaning therapies that have the potential to be safer and more effective than the current standard of care or other products in development, and that may have other advantages, such as superior scalability or ease of administration.

Our MultiStem® cell therapy, a patented and proprietary allogeneic “off-the-shelf” stem cell product, is our lead platform product and has shown promise for treating indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as certain other critical care conditions. MultiStem is currently being evaluated in several clinical-stage programs. Our most advanced program is focused on the treatment of ischemic stroke, which is being evaluated in a registrational trial in Japan, and in a Phase 3 clinical trial primarily in North America and Europe under a Special Protocol Assessment, or SPA. Our clinical development programs are focused on treating neurological conditions, inflammatory and immune disorders, cardiovascular disease, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients. These represent major areas of clinical need, as well as substantial commercial opportunities.

Learn more

We are committed to scientific excellence, patient safety, and developing safer and more effective therapies that can address significant unmet medical needs and enhance the lives of patients. We believe that this commitment will enable us to create substantial value for our shareholders. Athersys was established in October 1995, and since 2007, has been a publicly-traded company with its common stock traded on the NASDAQ Capital Market under the symbol “ATHX”. Athersys has operations in Cleveland, Ohio and Leuven, Belgium.


Business Strategy

Our principal business objective is to discover, develop and commercialize novel therapeutic products for disease indications that represent significant areas of clinical need and where we believe there is a substantial commercial opportunity. The key elements of our strategy are outlined below:

Our business strategy is to:

  • Advance our Lead Programs through Clinical Development to Registration and Commercialization;
    • Efficiently Conduct Clinical Development to Establish Clinical Proof-of-Concept, Evidence of Safety and Therapeutic Benefit;
    • Deepen our Understanding of Therapeutic Mechanisms of Action Evidence of Biological Activity;
    • Continue to Refine and Improve our Manufacturing and Related Processes and Technology;
  • Enter into Arrangements with Business Partners to Accelerate Development and Create Value;
  • Efficiently Explore New High Potential Therapeutic Applications, Leveraging Third-Party Research Collaborations and our Results from Related Areas; and
  • Continue to Expand our Intellectual Property Portfolio.